Innovative drugs achieve record-breaking overseas expansion! Total BD in the opening period exceeds $30 billion; 'R&D efficiency in China' highly regarded.

①The year 2026 began with a significant BD milestone, as the total upfront payments from License-out deals in early 2026 have already exceeded 39% of the total for the entire year of 2025; ②Innovent Bio and Eli Lilly and Co established a collaboration based on a novel molecule outside their existing pipelines, with the upfront payment not subject to additional confirmation conditions; ③CICC stated that China's innovative pharmaceuticals industry has entered the 2.0 era, transitioning from 'imitation through introduction' to 'innovation export'.

cls.cnFeb 17 14:16

Express News | Most innovative pharmaceutical concept stocks in the Hong Kong stock market rose, with Innovent Bio up more than 5%, Zai Lab, Connaught Biologics, and CSPC Pharma up more than 4%, and Wuxi Bio and Akeso Biologics up more than 3%.

BreakingsFeb 10 10:01

Haixi New Drug (02637) Subscribes to Financial Products

Haixi New Drug (02637) announced that on October 24, 2025, Fujian Haixi New Drug Creation Co., Ltd. (the Company), acting as an investor, utilized its idle funds to subscribe to (i) HKD 200 million worth of Fund-Linked Notes issued under the Series 2025-32 by Essence Global Investment Limited pursuant to its USD 1 billion Secured Structured Note Program (the Fund-Linked Notes Subscription); and (ii) up to HKD 200 million in China Rock Fund SPC (the China Rock Fund Subscription, collectively referred to as the Subscriptions along with the Fund-Linked Notes Subscription).

Zhitong FinanceFeb 5 16:37

Express News | The Implementing Regulations of the Drug Administration Law, which have undergone their first comprehensive revision in 23 years, will come into effect on May 15.

BreakingsJan 27 17:04

At the 'American Pharma Gala,' Chinese pharmaceutical companies have transitioned from 'optional consumption' to 'essential consumption.'

According to a JPMorgan report, China's innovative drug sector has evolved from being an 'optional choice' to becoming a category that multinational pharmaceutical companies must systematically evaluate during the asset screening phase. In certain areas such as oncology, autoimmune diseases, and metabolic conditions, some Chinese pharmaceutical companies have advanced to the forefront of global competition for the same therapeutic targets. This leadership is not primarily reflected in innovation of mechanisms but rather in clinical execution efficiency, patient enrollment speed, and the pace of advancing indications.

wallstreetcnJan 14 14:55

The boom in innovative drug business development has ignited the pharmaceutical sector of Hong Kong's stock market, with institutions noting that valuations of innovative drugs in Hong Kong remain highly attractive.

According to broker statistics, innovative drugs achieved five BDs (Business Development, referring to business development activities in the field of innovative drugs) within a week. On January 12, three major events occurred in second-generation IO therapy.

China SecuritiesJan 13 13:42